Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

NCT02325440 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Fingolimod
DRUG: Natalizumab

Sponsor

University Hospital Muenster

Collaborators

[object Object]